Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Jagsonpal Pharmaceuticals has portfolio of drugs focusing on gynaecology, orthopaedics, dermatology and child-care segments.
The company’s standalone net profit fell 8.4% to Rs 12.49 crore on 1.5% fall in net sales to Rs 72.95 crore in Q3 FY26 compared with Q3 FY25.
The appointment was made based on the recommendations of the company’s nomination and remuneration committee and audit committee, and subsequently approved by the board.
Vora is a Commerce graduate and a member of the Institute of Chartered Accountants of India (ICAI). He brings with him over 18 years of experience in finance, taxation, and allied laws, having worked across diverse industries.
Jagsonpal Pharmaceuticals engaged in the business of manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients.
The company’s standalone net profit jumped 38.6% to Rs 10.80 crore on 23.1% rise in revenue from operations to Rs 75.61 crore in Q1 FY26 over Q1 FY25.
Shares of Jagsonpal Pharma shed 0.46% to Rs 214.90 on the BSE.